High Prescription Rate of Medications With Rifampin Drug-drug Interactions in Patients With Diabetic Foot Osteomyelitis: Should Rifabutin Be Included in Clinical Trials for Adjunctive Therapy?

Open Forum Infect Dis. 2024 Oct 11;11(11):ofae582. doi: 10.1093/ofid/ofae582. eCollection 2024 Nov.

Abstract

Rifampin may improve diabetic foot osteomyelitis outcomes, but its extensive drug-drug interactions could hamper its use. Here, through a review of the medications prescribed to a cohort of 190 persons with diabetic foot osteomyelitis, we show that rifabutin, a rifamycin with fewer drug-drug interactions, would be easier to implement in practice.

Keywords: diabetic foot osteomyelitis; drug-drug interactions; rifamycins.

Publication types

  • Clinical Trial